Literature DB >> 1367569

The nasal delivery of peptides and proteins.

L Illum1.   

Abstract

Many drugs of the future will be therapeutically active peptides and proteins developed through recombinant-DNA technology. A major factor limiting their exploitation is the current lack of appropriate non-parenteral delivery systems. Nasal systems incorporating absorption enhancers may provide a convenient, efficient means of administering protein and peptide therapeutics.

Mesh：

Substances：

Year:  1991        PMID： 1367569     DOI： 10.1016/0167-7799(91)90091-u

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN： 0167-7799            Impact factor:   19.536


  4 in total

1.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  The role of rheological properties in mucociliary transport by frog palate ciliated model.

Authors:  D M Yu; G L Amidon; N D Weiner; D Fleisher; A H Goldberg
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

3.  Lack of effect of ammonium glycyrrhizinate on the morphology of ovine nasal mucosa in vitro.

Authors:  P M Reardon; D A Wall; T K Hart; P L Smith; C H Gochoco
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

4.  A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.

Authors:  M Roberts; A Bacon; R Rappuoli; M Pizza; I Cropley; G Douce; G Dougan; M Marinaro; J McGhee; S Chatfield
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.